EU pushes Bayer PAH drug Adempas further down the road

Eric Palmer Germany-based Bayer got an added boost today for its lung disease drug Adempas when the European Medicines Agency's Committee for Medicinal Products for Human Use recommended ...

Sanofi CEO: Our pipeline is in the top 5

Damian Garde Despite the recent FDA rebuke of the blockbuster hopeful Lemtrada, Sanofi CEO Chris Viehbacher believes his company is poised to cash in on "a whole raft of new products" ...

PTC slammed after EMA spurns its bid for early OK of DMD drug

John Carroll Shares of PTC Therapeutics took a hit this morning, dropping about 20% after the European Medicines Agency threw its considerable weight against the biotech's application ...

EMA reviews emergency contraceptives for their effectiveness in heavier women

Eric Palmer The European Medicines Agency will take a deep dive into whether over-the-counter emergency contraceptives–the so-called "morning-after pill"–don't ...

Merck KGaA takes the long view on troubled pharma biz

Damian Garde A series of setbacks has made things tough for Merck KGaA's drug development operation, but CEO Karl-Ludwig Kley said the German company remains committed to the long-term ...

Par Pharma nabs injectables specialist JHP for $490M in private-equity auction

Tracy Staton Generics maker Par Pharmaceutical inked a deal to pay $ 490 million for JHP Pharmaceuticals, a specialty pharma company owned by Warburg Pincus. Par will gain a portfolio ...

Pluristem shines in stem cell trial for muscle injury

Damian Garde Israel's Pluristem Therapeutics is back in the spotlight with some positive results for its stem cell therapy in treating patients with a muscle injury, giving the ...

NuPathe nixes Endo’s buyout offer to hook up with Teva

Tracy Staton FiercePharma News

J&J shipping out diagnostics biz for $4.2B

Damian Garde After more than a year of less-than-clandestine sale efforts, Johnson & Johnson has found a buyer for its diagnostics unit, signing a $ 4.2 billion deal with Carlyle ...

J&J takes Carlyle’s $4B offer for its Ortho Diagnostics unit

Tracy Staton Johnson & Johnson ($ JNJ) agreed to unload its Ortho Clinical Diagnostics unit to the private equity firm Carlyle Group in a $ 4.15 billion deal. FiercePharma News

Sanofi launches a new antibiotics effort, teams with Fraunhofer

John Carroll Sanofi is joining forces with researchers at Germany's Fraunhofer-Gesellschaft in the hunt for new antibiotics. The pharma giant is setting up a new collaboration that ...

Novo Nordisk eyes IPO for its IT subsidiary, taps new CFO to lead review

Tracy Staton Strategic reviews, sales and spinoffs are trendy in Big Pharma these days. Now, the Danish drugmaker Novo Nordisk has joined the bunch. Novo says it's weighing an initial ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS